Castle Biosciences (CSTL) raises 2026 revenue forecast as Q1 momentum centers on core tests

Executive snapshot

Castle Biosciences, a Nasdaq-listed diagnostics player, reported first-quarter 2026 results that underscore resilience in its core revenue drivers even as year-over-year topline headlines softened. Revenue came in at $83.7 million for the quarter, compared with $88.0 million in the same period a year earlier. Management attributes the year-over-year dip to strategic and policy factors rather than a collapse in demand—specifically, the Medicare coverage shift impacting DecisionDx-SCC and the May 2025 discontinuation of IDgenetix, along with a prior shift in commercial focus.

Revenue details and drivers

Breaking down the mix, non-dermatologic tests contributed $42.6 million of revenue, up from $25.0 million in the first quarter of 2025. The company notes continued strength in its core revenue drivers—DecisionDx-Melanoma and TissueCypher—where test volumes rose meaningfully on a year-over-year basis (double-digit growth in both lines: 16% for DecisionDx-Melanoma and 58% for TissueCypher). The headline takeaway is not merely the dollar figure but the composition: higher-value, core tests expanding even as a policy and portfolio timing drag overweighted the quarter.

In context, the quarter’s revenue was affected by the change in Medicare coverage for DecisionDx-SCC that took effect April 24, 2025, and by the re-focusing of commercial efforts alongside the discontinuation of IDgenetix in May 2025. The result is a quarter that reads more like a pivot point than a flat line, with meaningful gains in the resource-intensive core tests juxtaposed against a service line that bears the branding scars of strategic realignment.

Data highlights and momentum across tests

Castle called out new evidence supporting its market-leading DecisionDx-Melanoma test: a prospective, multicenter U.S.-based study demonstrated that patients with a predicted sentinel lymph node positivity risk of less than 5% had an actual positivity rate of 2.6%. Management framed this as reinforcing DecisionDx-Melanoma’s role in guiding sentinel lymph node biopsy decisions, aligning with guideline thresholds and strengthening the test’s evidentiary moat. It’s the sort of data point that economists would call “margin of safety” for adoption in clinical practice.

Guidance and outlook

Looking ahead, Castle raised its full-year 2026 revenue forecast to a range of $345–$355 million, up from the prior $340–$350 million range. Even with the quarter’s softness versus last year, the company signals confidence in the trajectory of core tests and in the ongoing benefit from newer evidence supporting adoption. The shift in guidance frames continued progress in core revenue drivers as the backbone of 2026 performance.

The release does not provide an EPS figure in this quarter, and investors will be watching for any EPS guidance, as well as the EPS consensus among sell-side analysts. In the meantime, revenue visibility from higher-volume DecisionDx-Melanoma and TissueCypher tests appears to be the anchor for sentiment on CSTL.

Operational highlights and leadership view

Management commentary centers on momentum and execution. The CEO emphasized the strength of the core revenue drivers and the company’s ongoing work to expand the body of evidence supporting its tests. The press release reiterates the timing of a conference call and webcast to discuss results, signaling continued investor engagement as the 2026 plan unfolds.

Implications for peers and the sector

The Q1 narrative for CSTL suggests a broader theme in molecular diagnostics: measured growth in high-value tests, tempered by policy shifts and portfolio realignments. Other players with similar portfolios may experience a comparable pull between core test growth and the drag from coverage changes or product discontinuations. For investors, the lesson is simple in theory: keep an eye on revenue forecast components—core test volumes, evidence generation, and payer dynamics—more than on any one quarter’s headline number.

Bottom line

Castle Biosciences’ Q1 2026 results offer a nuanced picture: robust growth in core tests and a raised full-year revenue forecast, tempered by a quarter-to-quarter mix that reflects policy and portfolio shifts. The stock will likely trade on the pace of adoption for DecisionDx-Melanoma and TissueCypher, the durability of non-dermatologic test revenues, and how quickly the market internalizes the revised 2026 revenue trajectory. In a world where the science keeps advancing, the real question is whether the data momentum translates into earnings leverage, and if the market assigns a premium to the incremental margin attached to high-value testing—an area where investors might expect closer attention to EPS and its consensus going forward.